Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
about
Current treatment of atypical mycobacteriosisPrimary drug-resistant tuberculosis in Hanoi, Viet Nam: present status and risk factorsPharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in TanzaniaThe Role of Adherence and Retreatment in De Novo Emergence of MDR-TBA Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, RussiaPharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment durationTherapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIVIsoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.AtriplaR/anti-TB combination in TB/HIV patients. Drug in focusEffects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patientsIsoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.Population pharmacokinetics of ethambutol in South African tuberculosis patients.Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosetsLow Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people.Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutolGlobal Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of EthambutolPharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIVReduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.Hair Analysis for Determination of Isoniazid Concentrations and Acetylator Phenotype during Antituberculous Treatment.Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.
P2860
Q28265322-99936EDB-502F-4BEE-A53A-53B4AED644EDQ28535281-7A7B1326-2665-402F-A8AC-4D2466812E18Q28550488-DB17DC4B-1E20-4613-B179-A27B5E5303D2Q28550707-04F87782-C485-47EB-BB3E-BC742E5F9D00Q28554618-695772CB-7C92-4FC1-B278-D285829A4DDAQ30377051-1E98F52F-E661-4BE0-A3A8-A286E49632D9Q30427912-D2DF9838-DF25-41D2-B631-3774E3129D2AQ30498213-4F50ED76-AC02-4A05-8CD1-896F81859E64Q33282527-4C471876-6C57-4758-87D9-02345CAD1582Q33433684-3671C3A7-C0C1-4D3F-92D4-9BD29E52CB85Q33547682-6C15523F-A606-437E-9A3A-4FD487E33EDAQ33797850-37785DC9-5B64-473E-A67C-E9D4E950AD72Q33797999-35545672-8C4E-4078-AF6C-113515DFD42AQ33798516-3CA54EA5-0C9B-40FA-B3A8-FDAD9D31E06FQ33843657-7EB009FF-CB7B-48A4-AE56-738EE571FDBAQ34083071-37C17885-26D8-4197-9F9A-F89E2BBD9347Q34150929-DE764697-6C7C-4CAD-80E2-077BD9F861ECQ34298988-F944E7BE-DAD1-487B-A744-68DA8BEB7597Q34561741-B936736B-549A-4AE7-8601-4EB6EB53CAE2Q34597564-5232B8DF-E627-4806-B9F3-C68376A7A72BQ34729493-402220C0-A513-49C9-983D-BAC3EDD53178Q35043048-29D74F73-21CE-4E3D-BCDB-CDDCDD17014EQ35120591-B6C22A1D-1F57-49C0-A347-359E6E36958CQ35167178-BB831819-1370-4DCF-A62B-35F2205658C0Q35191432-F27538F6-7BAD-41A4-AE6C-94637B5EB799Q35191463-02EEC378-AA05-4802-BB7F-D421F1E708F0Q35364313-462A9DAB-DB92-4E6F-BBEC-293D0FB3B7ADQ35584822-F2D764F3-8D64-477E-A36D-4B97D3FCDCADQ35745991-A4587D79-7084-4CEB-8B1C-1DED89805E33Q35778303-551E9D22-91C4-44D8-BA9D-8FF95B57F5C3Q35806375-688520FC-D204-4FC0-8D6F-BA85D6DE8049Q35837836-FC37105C-494E-49DA-9B1E-ABF2CDA408F1Q35911355-D98F606C-9CD9-4B0E-8C45-082DDDEBA072Q35941434-FB79E657-1801-4842-B66A-306CEDAD767CQ36018761-798E18F3-DF14-4347-B87A-91791081E11CQ36075981-131805EA-B8B6-4C76-95F2-AE6AA8215543Q36115081-68B332F5-3EFA-42CF-BFC5-F53DC3B2EB6FQ36290609-A299F5AF-0D4A-440E-8E46-0049CFFAF81FQ36311264-B429B05F-8BFD-4BF5-B8B1-FFF85F2FD510Q36364005-15112597-4F6B-405C-9211-1A39FD36945E
P2860
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Determinants of rifampin, ison ...... hort of tuberculosis patients.
@ast
Determinants of rifampin, ison ...... hort of tuberculosis patients.
@en
Determinants of rifampin, ison ...... hort of tuberculosis patients.
@nl
type
label
Determinants of rifampin, ison ...... hort of tuberculosis patients.
@ast
Determinants of rifampin, ison ...... hort of tuberculosis patients.
@en
Determinants of rifampin, ison ...... hort of tuberculosis patients.
@nl
prefLabel
Determinants of rifampin, ison ...... hort of tuberculosis patients.
@ast
Determinants of rifampin, ison ...... hort of tuberculosis patients.
@en
Determinants of rifampin, ison ...... hort of tuberculosis patients.
@nl
P2093
P2860
P1476
Determinants of rifampin, ison ...... hort of tuberculosis patients.
@en
P2093
André Burger
Jennifer Norman
Pete Smith
Peter I Folb
Peter Wash
P2860
P304
P356
10.1128/AAC.50.4.1170-1177.2006
P407
P577
2006-04-01T00:00:00Z